— Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., April 30, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational […]
— Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST — ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for
ROCKVILLE, Md., Aug. 29, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by
May 27, 2025 08:00 ET – Los resultados clínicos y de seguridad del estudio de Fase 1 del VCN-01 (zabilugene almadenorepvec) en pacientes con retinoblastoma refractario se presentarán en una sesión de pósteres en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) en Chicago el sábado 31 de mayo de 2025 –
May 27, 2025 08:00 ET – Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May 31st, 2025 – – Theriva senior management to attend the ASCO
May 15, 2025 16:00 ET – VCN-01 alcanza los criterios de valoración primarios de eficacia y seguridad para el adenocarcinoma pancreático ductal en el ensayo clínico de Fase 2b VIRAGE – – El 8 de mayo de 2025 se cerró una oferta pública que aumentó el saldo de caja de la empresa y amplía su
May 14, 2025 08:40 ET – VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial – – Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first quarter of 2026 – ROCKVILLE, Md., May 14, 2025
May 09, 2025 16:46 ET ROCKVILLE, Maryland, May 09, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada en fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy el cierre de su oferta pública de «mejores
Theriva Biologics anuncia el cierre de una oferta pública de 7,5 millones de dólares Read More »
May 08, 2025 07:05 ET ROCKVILLE, Maryland, May 08, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy el precio de su oferta pública de «mejores esfuerzos razonables» para la
Theriva Biologics anuncia el precio de su oferta pública de 7,5 millones de dólares Read More »
May 08, 2025 16:30 ET ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced “reasonable best efforts” public offering of
Theriva Biologics Announces Closing of $7.5 Million Public Offering Read More »
